Health Technology · Biotechnology · NSE: RUBICON · data 2026-10-09

Rubicon Research Limited

Health check: Strong (6.9/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹1,548.5

Market cap

₹25,388 cr

P/E

89.2

P/B

—

ROE

27.0%

ROCE

32.4%

Debt / equity

0.24

Dividend yield

0.10%

1-year return

149.8%

52-week high

₹1,899

52-week low

₹570.75

Operating margin

20.6%

Growth

Revenue (last 12 months)	₹1,936 cr
Net profit (last 12 months)	₹288 cr
Sales growth, 3 years (yearly)	64.7%
Profit growth, 3 years (yearly)	—

Chart patterns

Double top — breakdown (key level ₹1,740.5)

Similar companies

Anthem Biosciences Limited (ANTHEM) · Akums Drugs and Pharmaceuticals Limited (AKUMS) · Fermenta Biotech Ltd (FERMENTA) · Fabtech Technologies Limited (FABTECH) · Haleos Labs Ltd. (HALEOSLABS)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open RUBICON in NSE Scanner →